Cabozantinib (Cometriq)

Indications

  • Medullary Thyroid Cancer (see xxxx, [[xxxx]]): FDA-approved
  • Non-Small Cell Lung Cancer: investigational
  • Prostate Cancer: investigational
  • Bladder Cancer: investigational
  • Ovarian Cancer: investigational
  • Melanoma: investigational
  • Breast Cancer: investigational
  • Pancreatic Cancer: investigational
  • Heptaocellular Carcinoma: investigational
  • Renal Cancer: investigational

Pharmacology

  • Small Molecule Inhibitor of c-Met and VEGFR2 Tyrosine Kinases: inhibits tumor growth, metastasis, and angiogenesis

Metabolism

  • xxx

Administration

  • xxx

Dose Adjustment

  • Hepatic: xxx
  • Renal: xxx

Adverse Effects

Other Adverse Effects

  • xxx
  • xxx
  • xxx
  • xxx

References

  • xxx